Why is Nectar Lifesci. falling/rising?

As of 27-Jun, Nectar Lifescience Ltd is experiencing a decline in its stock price, currently at 22.19, reflecting a decrease of 0.31 or 1.38%. The stock has underperformed its sector today by 2.26% and has seen a trend reversal after three consecutive days of gains. In terms of returns, the stock has had a mixed performance; it has increased by 4.77% over the past week but has significantly underperformed over the last month and year, with declines of 18.42% and 28.21%, respectively. While the company has reported positive financial results, including a 40% growth in net profit and consistent performance over the last six quarters, it also faces challenges such as a weak long-term fundamental strength indicated by a -8.60% CAGR growth in operating profits over the last five years and a high debt to EBITDA ratio of 5.71 times, which may contribute to investor concerns.
In the broader market context, the stock's recent short-term return of 4.77% over the past week is notably better than the Sensex's increase of 2.00%, suggesting some positive sentiment in the immediate term. However, the long-term performance remains concerning, with the stock generating a return of -28.21% over the past year compared to a 6.08% gain in the Sensex. The high percentage of pledged promoter shares, at 99.6%, adds additional pressure on the stock in a falling market, further complicating its outlook. Overall, while there are some positive indicators, the combination of weak long-term fundamentals and high debt levels appears to be weighing down the stock's performance.